British Journal of Research Open Access

  • ISSN: 2394-3718
  • Journal h-index: 8
  • Journal CiteScore: 0.52
  • Journal Impact Factor: 0.45
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658


Comparison study on three medicinal plants used by Sudanese patients with type 2 diabetes mellitus on includes diabetic albino rat

Nitin M Kadam, R&D Formulation, Naari Pharmaceuticals Private Limited, India.

Quality by Design – New paradigm in Pharmaceutical Product Life Cycle. QbD has stirred pharma world w.r.t. new product filings and compliance. Enforcement of QbD in pharmaceutical development and continuing with product life cycle management has brought out an increased no of 483s to the no of manufacturers including giant pharma companies. And also decreased no of approvals after QbD enforcement. In this era of competition, quality has been given prime magnitude; failure to meet such quality allied goals produces massive shift of company in share of market. Recent past years have witnessed this through no of 483s to big pharma giants. “Quality could be planned and most of quality deficit arises in the way process is planned and developed”, this thought gives foundation to the concept of quality by design (QbD).